MC1R comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
SEM images of the radula can be found at Thompson, T.E.; Bebbington, A. (1973). "Scanning electron microscope studies of gastropod radulae". Malacologia. 14: 147–165. Tucker J.K. (2009). Recent cone species database. September 4th 2009 Edition Filmer R.M. (2001). A Catalogue of Nomenclature and Taxonomy in the Living Conidae 1758–1998. Backhuys Publishers, Leiden. 388pp Bouchet, P.; Fontaine, B. (2009). "List of new marine species described between 2002–2006". Census of Marine Life. Natural History Museum Rotterdam - photos of Conus shells Archived 2015-06-09 at the Wayback Machine Cone snail and conotoxins page The Conus Biodiversity website ConoServer Conidae from worldwide.conchology.com. Scroll down for many photographs. Pain-killer comes out of its shell (The Age news article) Venomous snails aid medical science (BBC News Article). ConeShell Collection Giancarlo Paganelli Archived 2019-12-21 at the Wayback Machine Cone Shells - Knights of the Sea. Alexander Medvedev's collection Cone Snail Video - Hunting Footage and Physiology Deadly Critters That Might Save Your Life (CNN) Baldomero "Toto" Olivera's short talk: Conus Peptides Archived 2015-04-06 at the Wayback Machine Zonatus Gallery Miller, John A. (1989). "The toxoglossan proboscis: structure and function". Journal of Molluscan Studies. 55 (2): 167–181. doi:10.1093/mollus/55.2.167. BBC Nature Video Cone snails are silent assassins of the sea, drugging sleeping fish before poisoning them Cone Snail Venom and AI May Lead to Drug Discovery | LANL
serious infections reactivation of hepatitis B reactivation of tuberculosis lethal hepatosplenic T-cell lymphoma (generally only when combined with 6-mercaptopurine) drug-induced lupus demyelinating central nervous system disorders psoriasis and psoriasiform skin lesions new-onset vitiligo Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported with infliximab. The FDA issued a warning to doctors appearing in the respective product labeling of infliximab instructing them to screen and monitor potential patients more carefully. The FDA issued a warning to doctors that there is an increased risk of lymphoma and other cancers associated with the use of infliximab and other tumor necrosis factor blockers in children and adolescents. Maintenance therapy with the drug (versus intermittent or sporadic therapy) lessens the likelihood of developing antibodies to infliximab which are known to reduce the efficacy of the drug. Combination treatment with methotrexate (an antifolate drug which suppresses the immune system) has been shown to reduce the formation of these antibodies in patients with rheumatoid arthritis and combination therapy with other immunosuppressants has been shown to reduce the likelihood of these antibodies being formed in Crohn's disease. The use of immunosuppressants may not be necessary in all diseases for which infliximab is indicated, and indiscriminant uses of these other immunosuppressants carry their own risks.
==== Underaged and pregnant offenders ==== Persons under the age of 18 at the time of their offence and pregnant women cannot be sentenced to death. Previously, offenders under 18 at the time of their offences would be indefinitely detained at the president's pleasure (TPP), with the normal period of detention having been between 10 and 20 years. These inmates would be released after receiving clemency from the President of Singapore, once they were assessed to be suitable for release. In 2010, the law was amended to allow judges to hand down a life imprisonment to offenders convicted of capital offences, but aged below 18 at the time of their crimes. They would be required to serve a minimum of 20 years before they can be reviewed for possible release. As for women who were pregnant at the time of their sentencing, they would automatically be sentenced to life imprisonment upon their conviction of any capital offences, though there have been no such cases as of yet. The first underaged offender to be sentenced to life imprisonment after the abolition of TPP was Myanmar national Zin Mar Nwe, a domestic worker who killed the mother-in-law of her employer in June 2018 at the age of 17. She received a life sentence in July 2023 after the High Court found her guilty of murder, with the trial judge Andre Maniam accepting that Zin was a minor and below 18 years of age when killing the 70-year-old victim and he thus opted to not impose a death sentence in her case.
Sources: en.wikipedia.org
On September 22, 2025, Trump and other U.S. Department of Human Service officials delivered speeches issuing a major agenda for combating autism. Warnings were for doctors not to recommend during pregnancy the pain- and fever-reducer acetaminophen, which is commonly used as an ingredient in Tylenol. These warnings were issued in spite of the fact that medical experts have found no link between autism and this ingredient, with autism generally established to be a result of complex neurological factors. Scientific American has reported that fever itself in the second [2nd] trimester is a risk factor for autism, and therefore the claims made by the Trump administration are counter-productive. Also on September 22, Trump also spoke in favor of and the FDA approved the use of the chemotherapy drug leucovorin to also help alleviate the symptoms of autism. However, the justification for this approval was based on limited evidence. A CBS News contributor said, "Not all children with autism have this defect, so there's a test you can do to assess whether that's what's at play. For those kids, leucovorin has been shown to help, particularly with speech, getting kids to be more verbal than they were before." The National Institute of Health (NIH) was also granted $50 million in funding for 13 projects to help transform autism research through the proposed Autism Data Science Initiative.
=== Consumer healthcare === GSK's consumer healthcare division, which earned £5.2 billion in 2013, sells oral healthcare, including Aquafresh, Macleans and Sensodyne toothpastes. GSK also previously owned the Lucozade and Ribena brands of soft drinks, but they were sold in 2013, to Suntory for £1.35bn. Other products include Abreva to treat cold sores; Night Nurse, a cold remedy; Breathe Right nasal strips; and Nicoderm and Nicorette nicotine replacements. In March 2014, it recalled Alli, an over-the-counter weight-loss drug, in the United States and Puerto Rico because of possible tampering, following customer complaints. On 18 July 2022, GSK formally spun off its consumer healthcare business as a separate entity, Haleon.
=== Other uses and occurrences === Pyrolysis is used to turn organic materials into carbon for the purpose of carbon-14 dating. Pyrolysis liquids from slow pyrolysis of bark and hemp have been tested for their antifungal activity against wood decaying fungi, showing potential to substitute the current wood preservatives while further tests are still required. However, their ecotoxicity is very variable and while some are less toxic than current wood preservatives, other pyrolysis liquids have shown high ecotoxicity, what may cause detrimental effects in the environment. Pyrolysis of tobacco, paper, and additives, in cigarettes and other products, generates many volatile products (including nicotine, carbon monoxide, and tar) that are responsible for the aroma and negative health effects of smoking. Similar considerations apply to the smoking of marijuana and the burning of incense products and mosquito coils. Pyrolysis occurs during the incineration of trash, potentially generating volatiles that are toxic or contribute to air pollution if not completely burned. Laboratory or industrial equipment sometimes gets fouled by carbonaceous residues that result from coking, the pyrolysis of organic products that come into contact with hot surfaces.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.